Max Klement
Board member
Max Klement is a Partner at Novo Holdings Venture Investments, based in London. He brings more than 15 years of experience across biotechnology and venture capital, with a focus on supporting biotech companies in financing strategy and the development of innovative medicines. Max currently serves on the boards of Kivu Bioscience, GlycoEra, F2G, and Myricx.
Prior to joining Novo Holdings, Max was a Principal at BGV, an early-stage life sciences venture capital firm, where he worked closely with emerging therapeutics companies from formation through growth. Earlier in his career, he held operational roles at Eden Biologics, a biologics CDMO, and at Hummingbird Bioscience, a company focused on antibody discovery and development through systems biology.
Max holds an MBA from INSEAD, a Ph.D. in Biochemical Engineering from the National University of Singapore, and a B.Sc. in Biochemical Engineering from the University of California, Irvine.